Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 34Neoplasm Metastasis 7Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms, Male 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Metastatic Breast Cancer With Intracranial Metastases 1Melanoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Esophagogastric Cancer 1GastroEsophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Carcinoma 1Breast Diseases 1Brain Neoplasms 1

Interventions

Octreotide 3Irinotecan 2cabazitaxel 1XRP6258 1Theophylline 1Surveys and Questionnaires 1Sugars 1Prednisone 1PHY 906 1Leucovorin 1Lapatinib 1Fluorouracil 1Erlotinib Hydrochloride 1Endoscopy 1Drugs, Investigational 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diarrhea × Lapatinib × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡